Severe Acute Respiratory Syndrome (SARS)

Infectious Disease Clinics of North America

Volumn 24, Issue 1, 2010, Pages 175-202

  Cleri, Dennis J ^a,b   Ricketti, Anthony J ^a,b   Vernaleo, John R ^c  

^a ST FRANCIS MEDICAL CENTER   (United States)

^b SETON HALL UNIVERSITY   (United States)

^c WYCKOFF HEIGHTS MEDICAL CENTER   (United States)

Author keywords

Acute respiratory distress syndrome (ARDS); Angiotensin converting enzyme 2 (ACE 2); Chinese horseshoe bats (genus Rhinolophus); Himalayan (masked) palm civets (Paguma larvata); Severe acute respiratory syndrome coronavirus; Superspreading events

Indexed keywords

BETA1A INTERFERON; CONSENSUS INTERFERON; CREATINE KINASE; INDOMETACIN; LACTATE DEHYDROGENASE; LOPINAVIR PLUS RITONAVIR; METHYLPREDNISOLONE; PEPTIDE VACCINE; RIBAVIRIN; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE;

ACUTE KIDNEY FAILURE; ANEMIA; ANTIVIRAL ACTIVITY; ATELECTASIS; AUTOPSY; BONE NECROSIS; BRONCHIECTASIS; CHILL; CLINICAL FEATURE; COMMON COLD; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG POTENTIATION; DYSPNEA; ENDOCRINE DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; GEOGRAPHIC DISTRIBUTION; HAEMOPHILUS INFECTION; HEADACHE; HEMODIALYSIS PATIENT; HEPATITIS; HISTORY OF MEDICINE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; IMMUNE RESPONSE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTOSIS; LYMPHOCYTOPENIA; MALAISE; MENTAL DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORAXELLACEAE INFECTION; MORTALITY; MYALGIA; NAUSEA; NEUTROPHILIA; NONHUMAN; PATHOGENESIS; PNEUMONIA; PNEUMOTHORAX; PREGNANCY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SORE THROAT; SPUTUM; STREPTOCOCCUS PNEUMONIA; SUPERINFECTION; TACHYCARDIA; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; VIROLOGY;

HUMANS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 76549087308     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2009.10.005     Document Type: Review

References (162)

1. Bitnun A., Allen U., Heurter H., et al. Children hospitalized with severe acute respiratory syndrome-related illness in Toronto. Pediatrics 112 (2003) e261
2. Gillim-Ross L., and Subbarao K. Emerging respiratory viruses: challenges and vaccine strategies. Clin Microbiol Rev 19 (2006) 614-636
3. Christian M.D., Poutanen S.M., Loutfy M.R., et al. Severe acute respiratory syndrome. Clin Infect Dis 38 (2004) 1420-1427
4. Lam C.W., Chan M.H., and Wong C.K. Severe acute respiratory syndrome: clinical and laboratory manifestations. Clin Biochem Rev 25 (2004) 121-132
5. Chen Y.C., Chang S.C., Tsai K.S., et al. Certainties and uncertainties facing emerging respiratory infectious diseases: lessons from SARS. J Formos Med Assoc 107 (2008) 432-442
6. Liu L., Fang Q., Deng F., et al. Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus. J Virol 81 (2007) 4694-4700
7. Ho H.T., Chang M.S., Wei T.Y., et al. Colonization of severe acute respiratory syndrome-associated coronavirus among health-care workers screened by nasopharyngeal swab. Chest 129 (2006) 95-101
8. Stockman L.J., Bellamy R., and Garner P. SARS: systematic review of treatment effects. PLoS Med 3 (2006) e343
9. Sung J.J., Wu A., Joynt G.M., et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 59 (2004) 414-420
10. Hasoksuz M., Alekseev K., Vlasova A., et al. Biologic, antigenic, and full-length genomic characterization of a bovine-like coronavirus isolated from a giraffe. J Virol 81 (2007) 4981-4990
11. Lau S.K., Woo P.C., Yip C.C., et al. Coronavirus HKU1 and other coronavirus infections in Hong Kong. J Clin Microbiol 44 (2006) 2063-2071
12. Li W., Shi Z., Yu M., et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 310 (2005) 676-679
13. Jiang S., He Y., and Liu S. SARS vaccine development. Emerg Infect Dis 11 (2005) 1016-1020
14. Sheahan T., Rockx B., Donaldson E., et al. Pathways of cross species transmission of synthetically reconstructed zoonotic severe acute respiratory syndrome cornonavirus. J Virol 82 (2008) 8721-8732
15. Yang H., Bartlam M., and Rao Z. Drug design targeting the main protease, the Achilles' heel of coronaviruses. Curr Pharm Des 12 (2006) 4573-4590
16. Cheng V.C., Lau S.K., Woo P.C., et al. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 20 (2007) 660-694
17. van der Hoek L. Human coronaviruses: what do they cause?. Antivir Ther 12 (2007) 651-658
18. Pyrc K., Berkhout B., and van der Hoek L. Antiviral strategies against human coronaviruses. Infect Disord Drug Targets 7 (2007) 59-66
19. Vabret A., Dina J., Gouarin S., et al. Human (non-severe acute respiratory syndrome) coronavirus infections in hospitalized children in France. J Paediatr Child Health 44 (2008) 176-181
20. Wang L.F., Shi Z., Zhang S., et al. Review of bats and SARS. Emerg Infect Dis 12 (2006) 1834-1840
21. Weiss S.R., and Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 69 (2005) 635-664
22. Chany C., Moscovici O., Lebon P., et al. Association of coronavirus infection with neonatal necrotizing enterocolitis. Pediatrics 69 (1982) 209-214
23. Stockman L.J., Haynes L.M., Miao C., et al. Coronavirus antibodies in bat biologists. Emerg Infect Dis 14 (2008) 999-1000
24. Bai B., Hu Q., Hu H., et al. Virus-like particles of SARS-like coronavirus formed by membrane proteins from different origins demonstrate stimulating activity in human dendritic cells. PLoS One 3 (2008) e2685
25. Cui J., Han N., Streicker D., et al. Evolutionary relationships between bat coronaviruses and their hosts. Emerg Infect Dis 13 (2007) 1526-1532
26. Normile D. Virology. Researchers tie deadly SARS virus to bats. Science 309 (2005) 2154-2155
27. Tang J.W., To K.F., Lo A.W., et al. Quantitative temporal-spatial distribution of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in post-mortem tissue. J Med Virol 79 (2007) 1245-1253
28. Nicholls J.M., Butany J., Poon L.L., et al. Time course and cellular localization of SARS-CoV nucleoprotein and RNA in lung from fatal cases. PLoS Med 3 (2006) e27
29. Hwang D.M., Chamberlain D.W., and Poutanen S.M. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol 18 (2005) 1-10
30. Gu J., and Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol 170 (2007) 1136-1147
31. Tse G.M., To K.F., Chan P.K., et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol 57 (2004) 260-265
32. Leung W.K., To K.F., Chan P.K., et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology 125 (2003) 1011-1017
33. Chu K.H., Tsang W.K., Tang C.S., et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int 67 (2005) 698-705
34. Leung T.W., Wong K.S., Hui A.C., et al. Myopathic changes associated with severe acute respiratory syndrome: a postmortem case series. Arch Neurol 62 (2005) 1113-1117
35. van den Brand J.M., Haagmans B.L., Leijten L., et al. Pathology of experimental SARS coronavirus infection in cats and ferrets. Vet Pathol 45 (2008) 551-562
36. Kuba K., Imai Y., and Penninger J.M. Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol 6 (2006) 271-276
37. Imai Y., Kuba K., and Penninger J.M. Lessons from SARS: a new potential therapy for acute respiratory distress syndrome (ARDS) with angiotensin converting enzyme 2 (ACE2). Masui 57 (2008) 302-310
38. Imai Y., Kuba K., and Penninger J.M. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol 93 (2008) 543-548
39. To K.F., and Lo A.W. Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2). J Pathol 203 (2004) 740-743
40. He W.P., Shu C.L., Li B.A., et al. Human LINE 1 endonuclease domain as a putative target of SARS-associated autoantibodies involved in the pathogenesis of severe acute respiratory syndrome. Chin Med J 5 (2008) 608-614
41. Chu C.M., Leung W.S., Cheng V.C., et al. Duration of RT-PCR positivity in severe acute respiratory syndrome. Eur Respir J 25 (2005) 12-14
42. Wong S.S., and Yuen K.Y. The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother 62 (2008) 437-441
43. Rabenau H.F., Cinati J., Morgenstern B., et al. Stability and inactivation of SARS coronavirus. Med Microbiol Immunol 194 (2005) 1-6
44. Kariwa H., Fujii N., and Takashima I. Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents. Dermatology 212 Suppl 1 (2006) 119-123
45. Darnell M.E., and Taylor D.R. Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products. Transfusion 46 (2006) 1770-1777
46. Hota B. Contamination, disinfection, and cross-colonization: are hospital surfaces reservoirs for nosocomial infection?. Clin Infect Dis 39 (2004) 1182-1189
47. Lim W., Ng K.C., and Tsang D.N. Laboratory containment of SARS virus. Ann Acad Med Singapore 35 (2006) 354-360
48. Chiu Y.C., Wu K.L., Chou Y.P., et al. Diarrhea in medical care workers with severe acute respiratory syndrome. J Clin Gastroenterol 38 (2004) 880-882
49. Hui D.S., and Chan P.K. Clinical features, pathogenesis and immunobiology of severe acute respiratory syndrome. Curr Opin Pulm Med 14 (2008) 241-247
50. Svoboda T., Henry B., Shulman L., et al. Public health measures to control the spread of the severe acute respiratory syndrome during the outbreak in Toronto. N Engl J Med 350 (2004) 2352-2361
51. Lee N., Hui D., Wu A., et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348 (2003) 1986-1994
52. Anderson R.M., Fraser C., Ghani A.C., et al. Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic. Philos Trans R Soc Lond B Biol Sci 359 (2004) 1091-1105
53. St John R.K., King A., de Jong D., et al. Border screening for SARS. Emerg Infect Dis 11 (2005) 6-10
54. Tsui P.T., Kwok M.L., Yuen H., et al. Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerg Infect Dis 9 (2003) 1064-1069
55. Sandrock C.E. Severe febrile respiratory illnesses as a cause of mass critical care. Respir Care 53 (2008) 40-53
56. Li Y., Duan S., Yu I.T., et al. Multi-zone modeling of probable SARS virus transmission by airflow between flats in Block E, Amoy Gardens. Indoor Air 15 (2005) 96-111
57. Wang X.W., Li J., Guo T., et al. Concentration and detection of SARS coronavirus in sewage from Xiao Tang Shan Hospital and the 309th Hospital of the Chinese People's Liberation Army. Water Sci Technol 52 (2005) 213-221
58. McKinney K.R., Gong Y.Y., and Lewis T.G. Environmental transmission of SARS at Amoy Gardens. J Environ Health 68 (2006) 26-30
59. Yip C., Chang W.L., Yeung K.H., et al. Possible meteorological influence on the severe acute respiratory syndrome (SARS) community outbreak at Amoy Gardens, Hong Kong. J Environ Health 70 (2007) 39-46
60. Cui Y., Zhang Z.F., Froines J., et al. Air pollution and case fatality of SARs in the People's Republic of China: an ecologic study. Environ Health 2 (2003) 15
61. Kan H.D., Chen B.H., Fu C.W., et al. Relationship between ambient air pollution and daily mortality of SARS in Beijing. Biomed Environ Sci 18 (2005) 1-4
62. Chu C.M., Cheng V.C., Hung I.F., et al. Viral load distribution in SARS outbreak. Emerg Infect Dis 11 (2005) 1882-1886
63. Hui D.S., Ip M., Tang J.W., et al. Airflows around oxygen masks: a potential source of infection?. Chest 130 (2006) 822-826
64. Somogyi R., Vesely A.E., Azami T., et al. Dispersal of respiratory droplets with open vs closed oxygen delivery masks: implications for the transmission of severe acute respiratory syndrome. Chest 125 (2004) 1155-1157
65. Ofner-Agostini M., Gravel D., McDonald L.C., et al. Cluster of cases of severe acute respiratory syndrome among Toronto healthcare workers after implementation of infection control precautions: a case series. Infect Control Hosp Epidemiol 27 (2006) 473-478
66. Christian M.D., Loutfy M., McDonald L.C., et al. Possible SARS coronavirus transmission during cardiopulmonary resuscitation. Emerg Infect Dis 10 (2004) 287-293
67. Ueno T., and Masuda N. Controlling nosocomial infection based on structure of hospital social networks. J Theor Biol 254 (2008) 655-666
68. Dell'Omodarme M., and Prati M.C. The probability of failing in detecting an infectious disease at entry points into a country. Stat Med 24 (2005) 2669-2679
69. Yang J.K., Feng Y., Yuan M.Y., et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 23 (2006) 623-628
70. Lee N., Chan P.K., Yu I.T., et al. Co-circulation of human metapneumovirus and SARS-associated coronavirus during a major nosocomial SARS outbreak in Hong Kong. J Clin Virol 40 (2007) 333-337
71. Peiris J.S., Chu C.M., Cheng V.C., et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361 (2003) 1767-1772
72. Babyn P.S., Chu W.C., Tsou I.Y., et al. Severe acute respiratory syndrome (SARS): chest radiographic features in children. Pediatr Radiol 34 (2004) 47-58
73. Stockman L.J., Massoudi M.S., Helfand R., et al. Severe acute respiratory syndrome in children. Pediatr Infect Dis J 26 (2007) 68-74
74. Booth C.M., Matukas L.M., Tomlinson G.A., et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 289 (2003) 2801-2809
75. Leung C.W., Kwan Y.W., Ko P.W., et al. Severe acute respiratory syndrome among children. Pediatrics 113 (2004) e535-e543
76. Wong R.S., Wu A., To K.F., et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ 326 (2003) 1358-1363
77. Hui D.S., Wong K.T., Antonio G.E., et al. Severe acute respiratory syndrome: correlation between clinical outcome and radiologic features. Radiology 233 (2004) 579-585
78. Che X.Y., Di B., Zhao G.P., et al. A patient with asymptomatic severe acute respiratory syndrome (SARS) and antigenemia from the 2003-2004 community outbreak of SARS in Guangzhou, China. Clin Infect Dis 43 (2006) e1-e5
79. Ksiezakowska K., Laszczyk M., Wilczynski J., et al. SARS-CoV infection and pregnancy. Ginekol Pol 79 (2008) 47-50
80. Lam C.M., Wong S.F., Leung T.N., et al. A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome. BJOG 111 (2004) 771-774
81. Wong S.F., Chow K.M., Leung T.N., et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol 191 (2004) 292-297
82. Shek C.C., Ng P.C., Fung G.P., et al. Infants born to mothers with severe acute respiratory syndrome. Pediatrics 112 (2003) e254
83. Li A.M., Chan C.H., and Chan D.F. Long-term sequelae of SARS in children. Paediatr Respir Rev 5 (2004) 296-299
84. Chu W.C., Li A.M., Ng A.W., et al. Thin-section CT 12 months after the diagnosis of severe acute respiratory syndrome in pediatric patients. AJR Am J Roentgenol 186 (2006) 1707-1714
85. Kwan B.C., Leung C.B., Szeto C.C., et al. Severe acute respiratory syndrome in dialysis patients. J Am Soc Nephrol 15 (2004) 1883-1888
86. Rainer T.H., Chan P.K., Ip M., et al. The spectrum of severe acute respiratory syndrome-associated coronavirus infection. Ann Intern Med 140 (2004) 614-619
87. Leung G.M., Chung P.H., Tsang T., et al. SARS-CoV antibody prevalence in all Hong Kong patient contacts. Emerg Infect Dis 10 (2004) 1653-1656
88. Lee C.C., Chen S.Y., Chang I.J., et al. Seroprevalence of SARS coronavirus antibody in household contacts. Epidemiol Infect 133 (2005) 1119-1122
89. Isakbaeva E.T., Khetsuriani N., Beard R.S., et al. SARS-associated coronavirus transmission, United States. Emerg Infect Dis 10 (2004) 225-231
90. Poutanen S.M., and Low D.E. Severe acute respiratory syndrome: an update. Curr Opin Infect Dis 17 (2004) 287-294
91. Chong W.P., Ip W.K., Tso G.H., et al. The interferon gamma gene polymorphism +874 A/T is associated with severe acute respiratory syndrome. BMC Infect Dis 6 (2006) 82
92. Antonio G.E., Wong K.T., Hui D.S., et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience. Radiology 228 (2003) 810-815
93. Chang Y.C., Yu C.J., Chang S.C., et al. Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT. Radiology 236 (2005) 1067-1075
94. Felice G.A. SARS, pneumothorax, and our response to epidemics. Chest 125 (2004) 1982-1984
95. Yu C.M., Wong R.S., Wu E.B., et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J 82 (2006) 140-144
96. Huang J.W., Chen K.Y., Tsai H.B., et al. Acute renal failure in patients with severe acute respiratory syndrome. J Formos Med Assoc 104 (2005) 891-896
97. Chen L.L., Hsu C.W., Tian Y.C., et al. Rhabdomyolysis associated with acute renal failure in patients with severe acute respiratory syndrome. Int J Clin Pract 59 (2005) 1162-1166
98. Griffith J.F., Antonio G.E., Kumta S.M., et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 235 (2005) 168-175
99. Chan M.H., Chan P.K., Griffith J.F., et al. Steroid-induced osteonecrosis in severe acute respiratory syndrome: a retrospective analysis of biochemical markers of bone metabolism and corticosteroid therapy. Pathology 38 (2006) 229-235
100. Wang S., Wei M., Han Y., et al. Roles of TNF-alpha gene polymorphisms in the occurrence and progress of SARS-CoV infection: a case-control study. BMC Infect Dis 8 (2008) 27
101. Lau E.M., Chan F.W., Hui D.S., et al. Reduced bone mineral density in male severe acute respiratory syndrome (SARS) patients in Hong Kong. Bone 37 (2005) 420-424
102. Leow M.K., Kwek D.S., Ng A.W., et al. Hypocortisolism in survivors of severe acute respiratory syndrome (SARS). Clin Endocrinol (Oxf) 63 (2005) 197-202
103. Chan H.L., Kwan A.C., To K.F., et al. Clinical significance of hepatic derangement in severe acute respiratory syndrome. World J Gastroenterol 11 (2005) 2148-2153
104. Yang Z., Xu M., Yi J.Q., et al. Clinical characteristics and mechanisms of liver damage in patients with severe acute respiratory syndrome. Hepatobiliary Pancreat Dis Int 4 (2005) 60-63
105. Davydow D.S., Desai S.V., Needham D.M., et al. Psychiatric morbidity in survivors of the acute respiratory distress syndrome: a systematic review. Psychosom Med 70 (2008) 512-519
106. Hawryluck L., Gold W.L., Robinson S., et al. SARS control and psychological effects of quarantine, Toronto, Canada. Emerg Infect Dis 10 (2004) 1206-1212
107. Styra R., Hawryluck L., Robinson S., et al. Impact on health care workers employed in high-risk areas during the Toronto SARS outbreak. J Psychosom Res 64 (2008) 177-183
108. Ko S.F., Lee T.Y., Huang C.C., et al. Severe acute respiratory syndrome: prognostic implications of chest radiographic findings in 52 patients. Radiology 233 (2004) 173-181
109. Wong K.T., Antonia G.E., Hui D.S., et al. Severe acute respiratory syndrome: thin-section computed tomography features, temporal changes, and clinicoradiologic correlation during the convalescent period. J Comput Assist Tomogr 28 (2004) 790-795
110. Emmanuel J.V., Pua U., Wansaicheong G.K., et al. Radiographic features of SARS in paediatric patients: a review of cases in Singapore. Ann Acad Med Singapore 35 (2006) 340-344
111. Schmidt M., Brixner V., Ruster B., et al. NAT screening of blood donors for severe acute respiratory syndrome coronavirus can potentially prevent transfusion associated transmissions. Transfusion 44 (2004) 470-475
112. Tang P., Louie M., Richardson S.E., et al. Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. CMAJ 170 (2004) 47-54
113. Tsao K.C., Chen G.W., Huang C.G., et al. False positive antibody results against human T-cell lymphotropic virus in patients with severe acute respiratory syndrome. J Med Virol 77 (2005) 331-336
114. Chan P.K., To W.K., Ng K.C., et al. Laboratory diagnosis of SARS. Emerg Infect Dis 10 (2004) 825-831
115. Keightley M.C., Sillekens P., Schippers W., et al. Real-time NASBA detection of SARS-associated coronavirus and comparison with real-time reverse transcription-PCR. J Med Virol 77 (2005) 602-608
116. Chan K.H., Poon L.L., Cheng V.C., et al. Detection of SARS coronavirus in patients with suspected SARS. Emerg Infect Dis 10 (2004) 294-299
117. Hung I.F., Cheng V.C., Wu A.K., et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis 10 (2004) 1550-1557
118. Pang R.T., Poon T.C., Chan K.C., et al. Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome. Clin Chem 52 (2006) 421-429
119. Yip T.T., Chan J.W., Cho W.C., et al. Protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid a protein as a biomarker potentially useful in monitoring the extent of pneumonia. Clin Chem 51 (2005) 47-55
120. Ohnishi K., Sakaguchi M., Kaji T., et al. Immunological detection of severe acute respiratory syndrome coronavirus by monoclonal antibodies. Jpn J Infect Dis 58 (2005) 88-94
121. Xu X., and Gao X. Immunological responses against SARS-coronavirus infections in humans. Cell Mol Immunol 1 (2004) 119-122
122. Li L., Gu J., Shi X., et al. Biosafety level 3 laboratory for autopsies of patients with severe acute respiratory syndrome: principles, practices, and prospects. Clin Infect Dis 41 (2005) 815-821
123. Sandrock C., and Stollenwerk N. Acute febrile respiratory illness in the ICU: reducing disease transmission. Chest 133 (2008) 1221-1231
124. Tsai Y.H., Wan G.H., Wu Y.K., et al. Airborne severe acute respiratory syndrome coronavirus concentrations in a negative-pressure isolation room. Infect Control Hosp Epidemiol 27 (2006) 523-525
125. Gao W., Tamin A., Soloff A., et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 362 (2003) 1895-1896
126. Chen Z., Zhang L., Qin C., et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol 79 (2005) 2678-2688
127. Bai B., Lu X., Meng J., et al. Vaccination of mice with recombinant baculovirus expressing spike or nucleocapsid protein of SARS-like coronavirus generates humoral and cellular immune responses. Mol Immunol 45 (2008) 868-875
128. Faber M., Lamirande E.W., Roberts A., et al. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol 86 (2005) 1435-1440
129. Woo P.C., Lau S.K., Tsoi H.W., et al. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine 23 (2005) 4959-4968
130. See R.H., Zakhartchouk A.N., Petric M., et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol 87 (2006) 641-650
131. Hu S., Wang Q.H., Wang X.J., et al. Expression of recombinant spike protein of SARS-coronavirus in vaccinia virus and analysis of its immunogenicity. Bing Du Xue Bao 23 (2007) 287-291
132. DiNapoli J.M., Kotelkin A., Yang L., et al. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci U S A 104 (2007) 9788-9793
133. Tsunetsugu-Yokota Y., Ato M., Takahashi Y., et al. Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses. Jpn J Infect Dis 60 (2007) 106-112
134. Luo F., Feng Y., Liu M., et al. Type IVB pilus operon promoter controlling expression of the severe acute respiratory syndrome-associated coronavirus nucleocapsid gene in Salmonella enterica serovar Typhi elicits full immune response by intranasal vaccination. Clin Vaccine Immunol 14 (2007) 990-997
135. Ranpirnase: amphibian ribonuclease A, P-30 protein-alfacell. Drugs R D 8 (2007) 120-124
136. Lee J.S., Poo H., Han D.P., et al. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J Virol 80 (2006) 4079-4087
137. Bukreyev A., Lamirande E.W., Buchholz U.J., et al. Mucosal immunization of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363 (2004) 2122-2127
138. Sui J., Li W., Roberts A., et al. Evaluation of human monoclonal 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol 79 (2005) 5900-5906
139. Imai Y., Kuba K., and Penninger J.M. Angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Cell Mol Life Sci 64 (2007) 2006-2012
140. Zhu Z., Chakraborti S., He Y., et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A 104 (2007) 12123-12128
141. ter Meulen J., van den Brink E.N., Poon L.L., et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 3 (2006) e237
142. Yang Z.Y., Werner H.C., Kong W.P., et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci U S A 102 (2005) 797-801
143. Fu C.Y., Huang H., Wang X.M., et al. Preparation and evaluation of anti-SARS coronavirus IgY from yolks of immunized SPF chickens. J Virol Methods 133 (2006) 112-115
144. Barnard D.L., Day C.W., Bailey K., et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother 17 (2006) 275-284
145. Lau A.C., So L.K., Miu F.P., et al. Outcome of coronavirus-associated severe acute respiratory syndrome using a standard treatment protocol. Respirology 9 (2004) 173-182
146. Tai D.Y. Pharmacologic treatment of SARS: current knowledge and recommendations. Ann Acad Med Singapore 36 (2007) 438-443
147. Saijo M., Morikawa S., Fukushi S., et al. Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus. Antiviral Res 66 (2005) 159-163
148. Chiou H.E., Liu C.L., Buttrey M.J., et al. Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers. Chest 128 (2005) 263-272
149. Amici C., Di Coro A., Ciucci A., et al. Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir Ther 11 (2006) 1021-1030
150. Wu C.J., Jan J.T., Chen C.M., et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrobial Agents Chemother 48 (2004) 2693-2696
151. Tan E.L.C., Ooi E.E., Lin C.-Y., et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis 10 (2004) 581-586
152. Chu C.M., Cheng V.C., Hung I.F., et al. Role of lopinavir/rotonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59 (2004) 252-256
153. Chan K.S., Lai S.T., Chu C.M., et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 9 (2003) 399-406
154. Golda A., and Pyrc K. Recent antiviral strategies against human coronavirus-related respiratory illnesses. Curr Opin Pulm Med 14 (2008) 248-253
155. Ikejiri M., Saijo M., Morikawa S., et al. Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents. Bioorg Med Chem Lett 17 (2007) 2470-2473
156. Xu Y., Jia Z., Zhou L., et al. Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab′)(2) in macaque. Int Immunopharmacol 7 (2007) 1834-1840
157. Tong T.R. SARS coronavirus anti-infectives. Recent Pat Antiinfect Drug Discov 1 (2006) 297-308
158. Kuhn J.H., Li W., Radoshitzky S.R., et al. Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies. Antivir Ther 12 (2007) 639-650
159. De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther 4 (2006) 291-302
160. Jackwood M.W. The relationship of severe acute respiratory syndrome coronavirus with avian and other coronaviruses. Avian Dis 50 (2006) 315-320
161. Ren W., Li W., Yu M., et al. Full-length genome sequences of two SARS-like coronaviruses in horseshoe bats and genetic variation analysis. J Gen Virol 87 (2006) 3355-3359
162. Booth C.M., and Stewart T.E. Severe acute respiratory syndrome and critical care medicine: the Toronto experience. Crit Care Med 31 Suppl 1 (2005) S53-S60